Home

Centre for Cancer Biomarkers CCBIO

CCBIO Seminar series

CCBIO Seminar - Jean-Christophe Bourdon

Title: "A decade of research on p53 sumarised".

ccbio_seminars_banner.jpg

CCBIO Seminars logo
Photo:
Colourbox/CCBIO

Apart from the interesting talks, the CCBIO seminars are a good way to meet CCBIO members and associates. Please feel free to inform others about this seminar as all are welcome both to the lecture and the pizza get-together afterwards.

Invited speakerJean-Christophe Bourdon, Division of Cancer Research, Jacqui Wood Cancer Centre, University of Dundee, United Kingdom.

Time: 14:30
Host: Bjørn Tore Gjertsen

Title: "A decade of research on p53 sumarised"

Abstract

All genetic models, experimental and clinical data indicate that TP53 gene play key roles in cancer formation, progression and treatment. For 30 years, it was thought that TP53 is a dedicated tumor-suppressor encoding a single transcription factor, p53, which protects cells from genotoxic stress. However, it is poorly understood how a single protein, p53, can be responsive to so many stress signals and orchestrates very diverse cell responses to maintain/restore cell/tissue functions.

The uncovering that TP53 gene physiologically expresses, in a tissue-dependent manner, not one p53 protein but twelves different p53 proteins with distinct biochemical activities (p53 isoforms) may prove fundamental to decipher the p53 pathway and improve cancer treatment. Over the last decade, all genetic animal models of p53 isoforms (zebrafish, drosophila and mouse), have consistently indicated that altering expression of a few p53 isoform, without affecting canonical p53 protein expression (ie. p53a), promote different pathologies: premature ageing, (neuro-)degenerative diseases, inflammation, cancer, embryo malformation and altered responses to ionising irradiation or infectious diseases. The p53 isoforms are dynamically reforming in depth the p53 field.

I will summarise a decade of research on p53 isoforms and present our latest experimental and clinical studies in breast cancer that could be extended to predict response to treatment in other type of cancer.